Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 13Other solid neoplasm 1

Conditions

Refractory or Relapsed Solid Tumors 1

Interventions

pembrolizumab 9Specimen Handling 7tislelizumab 6Pemetrexed 6Cisplatin 6Carboplatin 6fludarabine 5atezolizumab 5Interviews as Topic 5Injections 5Cyclophosphamide 5Bevacizumab 5Platinum 4Fluorouracil 4Educational Status 4Biopsy 4Standard of Care 3Practice Guidelines as Topic 3Nivolumab 3Methods 3Magnetic Resonance Spectroscopy 3Early Intervention, Educational 3Cetuximab 31,2-diaminocyclohexaneplatinum II citrate 3sintilimab 2sacituzumab govitecan 2fludarabine phosphate 2X-Rays 2Trastuzumab 2Radiotherapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
darolutamide × Other solid neoplasm × 30 days × Clear all
NCT07620041 2026-06-02

QLC5508 in Advanced Solid Tumors:: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction

Qilu Pharmaceutical Co., Ltd.

Phase 1 Not yet recruiting
48 enrolled
Other solid neoplasm

Refractory or Relapsed Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡